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Summary
Objective: To determine the prevalence of hepatitis B surface antigen (HBsAg)
amongst vaccinated children and controls aged 1—4 years in a rural community in
mid-western Nigeria.
Methods: The vaccinated children had received at least three doses of hepatitis B
vaccine. The vaccines included recombinant hepatitis B vaccine at birth and a
combined diphtheria, tetanus, pertussis (whole cell) plus hepatitis B (DTPw-HBV)
vaccine. HBsAg was determined by a rapid immunoassay method based on the
immunochromatographic sandwich principle. Two hundred and twenty-three children
and 219 controls were recruited into the study.
Results: The prevalence of HBsAg was significantly lower in the vaccinated group
(1.3%) than in the control group (4.6%, p = 0.04). The prevalence rates were sig-
nificantly higher inmales ( p = 0.02) and two-year birth cohort ( p = 0.01). The controls
were estimated to be at a six-fold higher risk of being positive for the surface antigen
than the vaccinated children. The vaccine effectiveness was estimated to be
approximately 80%.
Conclusion: These results confirm that hepatitis B vaccine protects against hepatitis B
surface antigen carriage and confirm immunogenicity of the combined DTPw-HBV
vaccine.
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Hepatitis B (HB) infection is a serious public health
problem, with two billion people infected world-
wide and 350 million suffering from chronic HB
infection. Globally it causes about 1.2million deaths
per year due to its various complications including
chronic hepatitis, liver cirrhosis, and liver cancer.1
Hepatitis B infection is hyper-endemic in Nigeria.2,3
In children, the infection occurs early in life and
studies report hepatitis B surface antigen (HBsAg)
prevalence rates of 20%,4 while in adult populations,
the rate varies from 10—38%.3,5 Hepatitis B is pre-
ventable through vaccination and studies have con-
firmed protection following vaccination in both
industrialized and non-industrialized commu-
nities.6—8 Hence mass vaccination ought to become
imperative on a global scale, as this will decrease
the reservoir of chronic carriers able to spread the
virus. Since 1992 the World Health Organization
(WHO) has recommended the inclusion of hepatitis
B vaccination in all national immunization programs
independent of hepatitis B carrier rate.9
GlaxoSmithKline Biologicals (GSK) developed the
first diphtheria, tetanus, and pertussis (whole cell) -
Hepatitis B combination (DTPw-HBV) vaccine, (Tri-
tanrixTM-HB). Studies have shown it to be safe and
immunogenic following a three-dose primary
course.10,11 In Nigeria, since 1998 GlaxoSmithKline
Biologicals has sponsored a vaccination programme
at Sabongidda-Ora, in Owan west Local Government
Area of Edo state in mid-western Nigeria. The pro-
gramme offers vaccination against all the Expanded
Programme on Immunization (EPI) diseases as well
as against hepatitis B. The hepatitis B vaccination
schedule includes a monovalent hepatitis B dose at
birth and three doses using the combined vaccine
given at 6, 10 and 14 weeks of age. Children who
were older than six weeks at the time of registering
into the programme did not receive the monovalent
HB dose at birth as they were vaccinated against
diphtheria, pertussis, tetanus and hepatitis B using
the combined vaccine. The primary objective of the
hepatitis B vaccination was to provide at least three
doses of the vaccine to all children.
Sabongidda-Ora was the only community in
Nigeria receiving hepatitis B vaccination at the time
the study was conducted. Vaccination coverage for
EPI antigens in this community in 1998 was 42%12 at a
time when hepatitis B vaccine was not adminis-
tered. A two-year post-programme evaluation
showed that vaccination coverage for EPI antigens
had increased to over 80% and hepatitis B vaccine
coverage (three doses) was 58%.13 It is important to
establish the benefit conferred by HB vaccination in
this programme. Accordingly, the objective of thisstudy was to investigate the prevalence of hepatitis
B surface antigen in vaccinated children as com-
pared to age-matched controls residing in the same
area.Methods
Study design
The study was conducted as a case control cross-
sectional design. All children recruited into the
study were aged between one to four years and
were generally healthy as established from the
medical history. The study took place between Feb-
ruary and March 2001 at the local vaccination clinic.
All subjects were required to visit the study site
once during which the medical history was checked,
physical examination and rapid blood test for HBsAg
determination were carried out.
Ethical approval
Ethical approval for the study was obtained from
The Research and Ethics Committee of the Lagos
State University College of Medicine, the Primary
Health Care Department of the Local Government
and the community leaders in accordance with local
customs. A cohort of unvaccinated children was
chosen, as there were children who were older than
the catchment age of the immunization programme
in the community when it began and others who
received vaccination excluding hepatitis B from
other sources.
Study population
The children enrolled into the study were living in
and around Sabongidda-Ora. They were invited
through various community meetings, schools, reli-
gious meetings and home visits undertaken by the
staff of the vaccination clinic.
The vaccinated group consisted of children with
immunization cards or those registered on the
clinic’s register with an immunization record. These
children had received three or four doses of HB
vaccine (either two doses of TritanrixTM-HB plus
Engerix-BTM at birth or three doses of TritanrixTM-
HB alone or three doses of TritanrixTM-HB plus
Engerix-BTM at birth). Children in the control group
were those whose records indicated they had not
been vaccinated against hepatitis B and those who
had not been registered at the study site. Recruit-
ment was carried out consecutively as the children
arrived at the clinic on each day of the study until
the study sample size was achieved.
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Table 1 Socio-demographic characteristics of the
subjects.
Variable Vaccinated
N (%)
Controls
N (%)
Age (years)
1 89 (39.9) 26 (11.9)
2 87 (39.0) 50 (22.8)
3 45 (20.2) 73 (33.3)
4 2 (0.9) 70 (32.0)
223 (100) 219 (100)
Mean age
(SD) years
1.8  0.78 2.9  1.00
Sex
Female 108 (48.4) 106 (48.4)
Male 115 (51.6) 113 (51.6)
223 (100) 219 (100)
Mean weight (SD) Kg 11.1  1.73 13.2  2.07
Table 2 Prevalence of hepatitis B surface antigen.
Variable Vaccinated
N (%)
Controls N
(%)
Fisher’s
exact
test
p-value
(1-sided)
Sex
Female 2/108 (1.9) 2/106 (1.9) 0.68Children with protein-energy malnutrition (using
the weight-for-age ratio, to calculate the cut-off
limits, with the 50th percentile Harvard Boston
standard as value)14 were excluded from the study
as well as those with mothers unwilling to allow
them to participate in the study. All mothers/guar-
dians of participating children provided oral
informed consent following a detailed explanation
of the rationale, aims and objectives of the study.
All oral consents were witnessed.
Sample size determination
The sample size was determined based on the fol-
lowing assumptions: the proportion of HBsAg in the
vaccinated group was estimated at 2% and in the
unvaccinated group at 20%. The power of the study
was set at 99% to detect a true difference of 18%
between both groups. A Fisher’s exact test with a
0.05 one sided-significance level was then applied
and resulted in a minimum estimated sample size of
220 subjects in each group.
Laboratory assay
Blood samples for the assay were taken from a finger
prick in each subject. Measurement of HBsAg was
performed at the study site by the principal inves-
tigator (OOO) using the commercially available Tri-
nity Biotech Uni-GoldTM HBsAg test kit (Trinity
Biotech Plc, Co, Wicklow, Ireland) for the rapid in
vitro, qualitative detection of HBsAg in whole blood.
This is a rapid immunoassay based on the immu-
nochromatographic sandwich principle. The test kit
is stable at temperatures of between 2—27 8C. The
sensitivity of the test kit is >99.5% and specificity
>99.5%.15
Data analysis
All data of subjects were collected along with the
HBsAg status. These were then analysed using Epi-
Info Version 6.04 b (CDC, USA & WHO Geneva,
Switzerland) software. Age, gender, and HBsAg posi-
tivity status for both groups were analysed by birth
cohort. Hepatitis B surface antigen prevalence was
determined by groups. The level of significance was
set at p < 0.05. The p values were one-sided.Male 1/115 (0.9) 8/113 (7.1) 0.02
Age (years)
1 1/89 (1.1) 0/26 (0.0) 1.00
2 2/87 (2.3) 7/50 (14.0) 0.01
3 0/45 (0.0) 3/73 (4.1) 0.23
4 0/2 (0.0) 0/70 (0.0) —
All subjects 3/223 (1.3) 10/219 (4.6) 0.04Results
A total of 446 children, 227 vaccinated and 219
unvaccinated were recruited into the study. How-
ever, four subjects in the vaccination group were
excluded from the final analysis as they were lessthan one year of age. Thus 442 subjects consisting of
223 (50.5%) vaccinated children and 219 (49.5%)
unvaccinated were included in the analysis
(Table 1). There were 214 (48%) females and 228
(52%) males in the study population, with the gender
distribution being similar in each group. Other
demographic characteristics of the two groups were
similar except that the unvaccinated children were
significantly older in age and weighed more
(p = 0.001) than the vaccinated group.
In the vaccinated cohort, one child (0.5%)
received the monovalent HB dose at birth plus
two doses of the combined vaccine; 106 (47.5%)
received only three doses (omitting the dose at
birth) of the combined vaccine and 116 (52%)
received four doses (HB dose at birth plus three
doses of the combined vaccine). The prevalence
of HBsAg is shown on Table 2. Three subjects in
the vaccinated group (1.3%) were positive compared
to ten (4.6%) in the unvaccinated group (p = 0.04).
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cohort was 6.43 (95% confidence interval = 1.3 <
OR < 27.6), and had a six-fold higher risk of being
positive for the surface antigen. The risk was found
to be significant (Mantel-Haenzel summary chi-
square = 6.03; p = 0.01). The prevalence of the sur-
face antigen was significantly higher amongst males
and the two-year birth cohort. The three vaccinated
subjects who were positive for the surface
antigen did not receive the hepatitis B dose at
birth. There was no statistically significant differ-
ence in the prevalence rate of the surface antigen
amongst vaccinated children who received the
hepatitis B vaccine dose at birth and those who
did not. Using a Poisson model with a correction
for age, the vaccine effectiveness was 80.0%
(20.0% < 95%CI < 95.0%).Discussion
The HBsAg rate (4.6%) obtained amongst the unvac-
cinated children was much lower than previous
reports amongst children (10—23%) in Nigeria.2,3,5
This could be explained as follows. First, the studies
that report higher values are hospital-based and
were conducted amongst sick children who may
have had a higher level of exposure to the virus
relative to the healthy children in the community.
Thus, the actual HBsAg rate amongst children in the
community may be much lower than has been pre-
viously reported. Secondly, the lower rates in this
study may be due to the sensitivity of the test kit
used, but this is unlikely as the manufacturers quote
both sensitivity and specificity rates of 99.5%.
As was to be expected, the HBsAg rate amongst
the vaccinated children was significantly lower than
amongst the unvaccinated. At least 98% of the
vaccinated group were negative for the surface
antigen, while the unvaccinated children had a
significant risk (six-fold) of being carriers of hepa-
titis B surface antigen. These results are similar to
studies by other researchers who found significant
reductions in the HBsAg rate post vaccination and a
protective efficacy of between 67—94%.8,16,17 The
80% vaccine efficacy obtained in this study (though
slightly lower than expected) is comparable to the
67% rate reported from Egypt,17 and like others
confirms the immunogenicity of the combined
DPTW-HB vaccine.
10,11 Such a high level of vaccine
efficacy is likely to impact positively and prevent
the transmission of hepatitis B infection in the
community.
The significantly higher proportion of males and
children aged two years who were positive for the
surface antigen may be related to a more intenselevel of exposure. Hepatitis B infection is more
commonly transmitted in children through the hor-
izontal route and this may explain the higher rates
of the surface antigen in the two-year-olds as pre-
school activities start at this age. The low rates
amongst the older children cannot be accounted
for. The three cases of HBsAg in the vaccinated
group are apparent vaccine failures. The failure
rate of 1.3% is similar to rates of between 0.7—3%
reported by other researchers.16—18 These three
cases did not receive hepatitis B vaccine at birth
and may have been exposed to the virus before
vaccination. Furthermore, a hypothesis of an unpro-
ven intrauterine transmission of the virus from a
carrier mother to her foetus has been proposed as
one of the causes of vaccine failure.19
In conclusion, this study found that the preva-
lence of HBsAg was significantly lower amongst
vaccinated children compared with the unvacci-
nated group and that vaccine effectiveness was
80%. We suggest that more community-based stu-
dies be conducted amongst children to provide up-
to-date information on HBsAg status in view of the
low prevalence obtained in this study. In addition,
we recommend that HB vaccination be commenced
nationwide to further reduce the risks associated
with the disease.
Limitations of the study
Serologic results presented in this study do not
represent conventional evaluation of vaccine immu-
nogenicity or efficacy but rather evaluation of the
ability of the HB vaccination to provide protection
and reduce susceptibility to the virus in vaccinated
subjects. In addition, information on the HBsAg
status of the children’s family members and expo-
sure of the children to the virus were not available.
These factors may have an impact on the results of
the study as the intra-familial clustering of the
infection is well known. The HBsAg prevalence in
the unvaccinated group employed to determine the
sample size was overestimated compared to the
results of the study. This led to a sample size that
was underpowered, though it was able to detect a
statistically significant difference in the HBsAg pre-
valence between both vaccinated and unvaccinated
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